Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Kova vs Obu Health

Kova
Graded #498

Lower grade

vs+15.600000000000001
Obu Health
Graded #332

Higher grade

The verdict

Obu Health takes it — 59.9/100 to 44.3/100.

Obu Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Obu Health is a Las Vegas-based multi-product telehealth platform offering compounded semaglutide from $190/month and compounded tirzepatide from $239/month, plus NAD+ and sermorelin add-ons.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueObu Health +24
20
44
Dose & formulationObu Health +24
40
64
Clinical oversightObu Health +13
71
84
Labs & monitoringObu Health +1
52
53
FulfillmentObu Health +13
61
74
Contract termsObu Health +6
25
31
Kova · left barObu Health · right bar

The numbers

MetricKovaObu Health
WeighScore44.3/10059.9/100
GradeCC
Scorecard rank#498#332
SemaglutideNot disclosed$190/mo (starting dose, plus a separate fee, compounded)
TirzepatideNot disclosed$239/mo (starting dose, plus a separate fee, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Kova

Graded #498 · C

Strengths

  • Publishes the full price ladder for all three plan terms — intro month and renewal rate — directly in its FAQ
  • Medication is included in the plan price, with no separate pharmacy charge
  • States plainly that its compounded GLP-1s are 'not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality'
  • Companion app tracks weight, protein and side effects, with medication schedule reminders
  • You are not charged unless a provider approves treatment

Where it loses points

  • At $449 per 4 weeks, the standing 1-month plan is among the most expensive compounded GLP-1 options we track
  • The advertised $129 is the 6-month plan's intro month only — that plan then renews at $1,794 every 24 weeks
  • Billed every 4 weeks rather than monthly, which is 13 charges a year instead of 12
  • Never names which GLP-1 molecule is dispensed — only 'compounded, non-FDA-approved GLP-1 medications'
  • No pharmacy or prescribing medical group is named anywhere on the site
Obu Health

Graded #332 · C

Strengths

  • LegitScript-certified with publicly displayed ID (44206977)
  • Two named 503A compounding-pharmacy partners (Manifest Pharmacy SC + RX Compounding Store FL) — transparency above category baseline
  • Lower advertised semaglutide starting price ($190) than most multi-product peer platforms
  • Multi-product offering (GLP-1s + NAD+ + sermorelin + generic ED + birth control) for single-platform users
  • 24-hour US board-certified physician response window

Where it loses points

  • Per-dose pricing tiers not transparently published on product pages — only 'starting from' prices visible
  • No explicit state-coverage list disclosed; FAQ confirms restrictions exist 'based on state' without enumeration
  • Medical director not named publicly
  • No published consultation fee disclosure — unclear whether physician visit is included in medication price
  • All sales final per FAQ ('Federal and State law do not allow medication returns')

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard